Studies prodigiosin and pioglitazone effects on lung cancer immune signals
Observes how two small molecules may affect immune checkpoint proteins in lung cancer.
Plain-language title generated from the registry record
Registry title: Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)
Key facts
- Where
- Cairo, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults over 50 years old who have non-small cell lung cancer (NSCLC).
- Age
- Over 50 years old
- Sex
- All sexes can join
- Disease stage
- Non-small cell lung cancer (NSCLC)
Main reasons for not taking part
- Lung cancer patients with any cancer other than NSCLC
- Incomplete data or an incomplete histopathology diagnosis report
Read by machine on 9 November 2026.
Where in Egypt
- Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research LabCairo, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ain Shams University
- Trial code
- NCT06502249
- Record updated
- 16 July 2024
- Original description
Lung cancer is one of the most common and serious types of cancer. Lung tumor cells exploit immune checkpoint proteins (ICPs) to maintain immune tolerance and thus promote tumor progression and invasion. Inhibition of ICPs using antibody therapies is one of the most common approaches for the treatment of lung cancer. Unfortunately, these antibody-based therapies can lead to severe adverse events. Moreover, a significant number of patients do not respond to immune checkpoint inhibition due to tumor heterogeneity and the immunosuppressive tumor immune microenvironment (TIME). The use of small molecule targeted approach instead of antagonizing antibodies may have the potential advantage of being able to target multiple ICPs in TIME with a single agent as well as improved tumor distribution.Read full original descriptionShow less
Modulatory Effect of Prodigiosin or Pioglitazone on Tumor Immune Microenvironment and the Crosstalk to Immune-Checkpoint Protein(s)
Lung cancer is one of the most common and serious types of cancer. Lung tumor cells exploit immune checkpoint proteins (ICPs) to maintain immune tolerance and thus promote tumor progression and invasion. Inhibition of ICPs using antibody therapies is one of the most common approaches for the treatment of lung cancer. Unfortunately, these antibody-based therapies can lead to severe adverse events. Moreover, a significant number of patients do not respond to immune checkpoint inhibition due to tumor heterogeneity and the immunosuppressive tumor immune microenvironment (TIME). The use of small molecule targeted approach instead of antagonizing antibodies may have the potential advantage of being able to target multiple ICPs in TIME with a single agent as well as improved tumor distribution.
Inclusion: Adults over 50 years old with NSCLC.
Exclusion: Lung cancer patients with any cancer other than NSCLC; Lung cancer patients with incomplete data or incomplete histopathology diagnosis report.